Mycosis fungoides primary prevention: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
No edit summary
 
(7 intermediate revisions by 2 users not shown)
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{Cutaneous T cell lymphoma}}
{{Mycosis fungoides}}
{{CMG}}; {{AE}} {{S.G.}}
{{CMG}}; {{AE}} {{S.G.}}


==Overview==
==Overview==
There are no established measures for the secondary prevention of mycosis fungoides but recommended effective measures for the secondary prevention of mycosis fungoides is follow up patients with active or progressive disease. every 4–6 weeks.
* There are no established measures for the secondary prevention of mycosis fungoides but recommended that effective measures for the [[secondary]] [[Prevention (medical)|prevention]] of mycosis fungoides is follow up [[Patient|patients]] with active or progressive [[disease]], every 4–6 weeks.
 
==Secondary Prevention==
effective measures for the secondary prevention of mycosis fungoides is follow up patients with active or progressive disease. every 4–6 weeks.<ref name="WillemzeHodak2018">{{cite journal|last1=Willemze|first1=R|last2=Hodak|first2=E|last3=Zinzani|first3=P L|last4=Specht|first4=L|last5=Ladetto|first5=M|title=Primary cutaneous lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†|journal=Annals of Oncology|volume=29|issue=Supplement_4|year=2018|pages=iv30–iv40|issn=0923-7534|doi=10.1093/annonc/mdy133}}</ref>
 


==Primary Prevention==
*There are no established [[Risk factor|risk factors]] for mycosis fungoides.
* The [[Risk factor|risk factors]] in the development of mycosis fungoides is environmental and occupational exposure include <ref>{{Cite journal
| author = [[A. S. Whittemore]], [[E. A. Holly]], [[I. M. Lee]], [[E. A. Abel]], [[R. M. Adams]], [[B. J. Nickoloff]], [[L. Bley]], [[J. M. Peters]] & [[C. Gibney]]
| title = Mycosis fungoides in relation to environmental exposures and immune response: a case-control study
| journal = [[Journal of the National Cancer Institute]]
| volume = 81
| issue = 20
| pages = 1560–1567
| year = 1989
| month = October
| pmid = 2795681
}}</ref><ref name="pmid1857968">{{cite journal |vauthors=Hall WW, Liu CR, Schneewind O, Takahashi H, Kaplan MH, Röupe G, Vahlne A |title=Deleted HTLV-I provirus in blood and cutaneous lesions of patients with mycosis fungoides |journal=Science |volume=253 |issue=5017 |pages=317–20 |date=July 1991 |pmid=1857968 |doi= |url=}}</ref><ref>{{Cite journal
| author = [[S. K. Ghosh]], [[J. T. Abrams]], [[H. Terunuma]], [[E. C. Vonderheid]] & [[E. DeFreitas]]
| title = Human T-cell leukemia virus type I tax/rex DNA and RNA in cutaneous T-cell lymphoma
| journal = [[Blood]]
| volume = 84
| issue = 8
| pages = 2663–2671
| year = 1994
| month = October
| pmid = 7522638
}}</ref>
**[[Bacterial infection]] of the [[skin]]
**Long term exposure to [[chemicals]]
**[[Smoking]]
**[[Medication|Medications]]
**Long term [[sun exposure]]
**[[Viral infections]] (Human T lymphotropic virus type I)


==References==
==References==

Latest revision as of 04:05, 11 February 2019

Mycosis fungoides Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Mycosis Fungoides from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

X-Ray

CT Scan

MRI

Echocardiography and Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Mycosis fungoides primary prevention On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Mycosis fungoides primary prevention

All Images
X-rays
Echo and Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Mycosis fungoides primary prevention

CDC on Mycosis fungoides primary prevention

Mycosis fungoides primary prevention in the news

Blogs on Mycosis fungoides primary prevention

Directions to Hospitals Treating Mycosis fungoides

Risk calculators and risk factors for Mycosis fungoides primary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sogand Goudarzi, MD [2]

Overview

  • There are no established measures for the secondary prevention of mycosis fungoides but recommended that effective measures for the secondary prevention of mycosis fungoides is follow up patients with active or progressive disease, every 4–6 weeks.

Primary Prevention

References

  1. ↑ A. S. Whittemore, E. A. Holly, I. M. Lee, E. A. Abel, R. M. Adams, B. J. Nickoloff, L. Bley, J. M. Peters & C. Gibney (1989). "Mycosis fungoides in relation to environmental exposures and immune response: a case-control study". Journal of the National Cancer Institute. 81 (20): 1560–1567. PMID 2795681. Unknown parameter |month= ignored (help)
  2. ↑ Hall WW, Liu CR, Schneewind O, Takahashi H, Kaplan MH, Röupe G, Vahlne A (July 1991). "Deleted HTLV-I provirus in blood and cutaneous lesions of patients with mycosis fungoides". Science. 253 (5017): 317–20. PMID 1857968.
  3. ↑ S. K. Ghosh, J. T. Abrams, H. Terunuma, E. C. Vonderheid & E. DeFreitas (1994). "Human T-cell leukemia virus type I tax/rex DNA and RNA in cutaneous T-cell lymphoma". Blood. 84 (8): 2663–2671. PMID 7522638. Unknown parameter |month= ignored (help)

Template:WH Template:WS

Retrieved from "https://www.wikidoc.org/index.php?title=Mycosis_fungoides_primary_prevention&oldid=1548167"